RxDoctor Payments Data

Svenja Albrecht, MD

Infectious Disease · Jackson, MSNPI 1962539577

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (57.9%), consulting fees and education — rather than concentrated in one kind of arrangement. 9 manufacturers reported payments, led by Theratechnologies Inc. at 40.5% of the total. Reporting peaked in 2021 at $2,268 and has fallen 89.8% since, to $232 in 2025. Among infectious disease clinicians in MS with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$4,992in general payments, 2019–2025

Across 90 payments — averaging $55.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Theratechnologies Inc.$2K
  • AbbVie$1K
  • Gilead$1K
  • Johnson & Johnson$100
  • Merck$71
  • Melinta Therapeutics, LLC$26
  • plus $68 from 3 others

What the payments were for

  • Consulting fees$2,00040%
  • Food & beverage$2,89258%
  • Education$1002%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,992 in reported general payments places this provider in the 90th percentile of 36 infectious disease providers in Mississippi.

See all infectious disease providers in Mississippi

Medicare billing

Part B allowed, 2024
$23,469
Medicare patients
100
Services billed
205

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GenvoyaElviteg/Cob/Emtri/Tenof Alafen12$42,648
Daptomycin11$6,358
Entecavir15$740

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadGenvoya$1,270$42,64812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 36 infectious disease providers in Mississippi.

Other infectious disease in Jackson

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →